Prognostic role of translocator protein and oxidative stress markers in chronic lymphocytic leukemia patients treated with bendamustine plus rituximab

De Rosa,Aniello; Zappavigna,Silvia; Villa,Maria  Rosaria; Improta,Salvatore; Cesario,Elena; Mastrullo,Lucia; Caraglia,Michele; Stiuso,Paola

doi:10.3892/ol.2014.2817

Prognostic role of translocator protein and oxidative stress markers in chronic lymphocytic leukemia patients treated with bendamustine plus rituximab

Authors:
- Aniello De Rosa
- Silvia Zappavigna
- Maria Rosaria Villa
- Salvatore Improta
- Elena Cesario
- Lucia Mastrullo
- Michele Caraglia
- Paola Stiuso
View Affiliations

Affiliations: Local Sanitary Agency, Naples 3 Southern, Torre del Grecco, Naples I‑80059, Italy, Department of Biochemistry, Biophysics and General Pathology, Second University of Naples, Naples I‑80138, Italy, Hematology Unit, San Gennaro Hospital, Naples I‑80131, Italy
Published online on: December 19, 2014 https://doi.org/10.3892/ol.2014.2817
Pages: 1327-1332

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Principally located in the outer mitochondrial membrane, the translocator protein (TSPO) is an 18‑kDa transmembrane protein that is a key component of the mitochondrial permeability transition pore. TSPO is associated with a number of biological processes, including apoptosis, the regulation of cellular proliferation, porphyrin transport and heme biosynthesis, immunomodulation, anion transport and the regulation of steroidogenesis. Thus, numerous studies have proposed TSPO as a promising target for novel therapeutic agents, particularly for the treatment of cancer. In the present study, the response of 30 consecutive chronic lymphocytic leukemia (CLL) patients to bendamustine and rituximab treatment was evaluated according to TSPO expression levels. Furthermore, thiobarbituric acid reactive substances (TBARS) and nitric oxide (NO) levels, as well as caspase‑3 activity were determined. Compared with the lymphocytes of healthy donors, the 30 consecutive CLL patients exhibited increased TSPO expression levels, decreased TBARS and NO levels and reduced caspase‑3 activity. Six months after the treatment commenced, the TSPO/mitochondria ratio resembled that of the healthy controls in 24/30 CLL patients. In addition, an increase in TBARS and NO levels, two markers of oxidative stress, and a potentiation of caspase‑3 activity in all responder patients was observed. Notably, the six patients who appeared to be resistant to treatment also displayed higher TSPO levels, and lower caspase‑3 activity and TBARS levels. These data indicate that TSPO expression may be a molecular prognostic factor in CLL patients.

View Figures

View References

1	McEnery MW, Snowman AM, Trifiletti RR and Snyder SH: Isolation of the mitochondrial benzodiazepine receptor: association with the voltage-dependent anion channel and the adenine nucleotide carrier. Proc Natl Acad Sci. 89:3170–3174. 1992. View Article : Google Scholar : PubMed/NCBI
2	Casellas P, Galiegue S and Basile AS: Peripheral benzodiazepine receptors and mitochondrial function. Neurochem Int. 40:475–486. 2002. View Article : Google Scholar : PubMed/NCBI
3	Sutter AP, Maaser K, Höpfner M, et al: Specific ligands of the peripheral benzodiazepine receptor induce apoptosis and cell cycle arrest in human esophageal cancer cells. Int J Cancer. 102:318–327. 2002. View Article : Google Scholar : PubMed/NCBI
4	Zisterer, Campiani G, Nacci V and Williams DC: Pyrrolo-1,5-benzoxazepines induce apoptosis in HL-60, Jurkat, and Hut-78 cells: a new class of apoptotic agents. J Pharmacol Exp Ther. 293:48–59. 2000.PubMed/NCBI
5	Carayon P, Portier M, Dussossoy D, Bord A, Petitprêtre G, Canat X, Le Fur G and Casellas P: Involvement of peripheral benzodiazepine receptors in the protection of hematopoietic cells against oxygen radical damage. Blood. 87:3170–3178. 1996.PubMed/NCBI
6	Austin CJ, Kahlert J, Kassiou M and Rendina LM: The translocator protein (TSPO): a novel target for cancer chemotherapy. Int J Biochem Cell Biol. 45:1212–1216. 2013. View Article : Google Scholar : PubMed/NCBI
7	Katz Y, Eitan A and Gavish M: Increase in peripheral benzodiazepine binding sites in colonic adenocarcinoma. Oncology. 47:139–142. 1990. View Article : Google Scholar : PubMed/NCBI
8	Cornu P, Benavides J, Scatton B, Hauw JJ and Philippon J: Increase in omega 3 (peripheral-type benzodiazepine) binding site densities in different types of human brain tumours. A quantitative autoradiography study. Acta Neurochir (Wien). 119:146–152. 1992. View Article : Google Scholar
9	Hardwick M, Fertikh D, Culty M, Li H, Vidic B and Papadopoulos V: Peripheral-type benzodiazepine receptor (PBR) in human breast cancer: correlation of breast cancer cell aggressive phenotype with PBR expression, nuclear localization, and PBR-mediated cell proliferation and nuclear transport of cholesterol. Cancer Res. 59:831–842. 1999.PubMed/NCBI
10	Katz Y, Ben-Baruch G, Kloog Y, Menczer J and Gavish M: Increased density of peripheral benzodiazepine-binding sites in ovarian carcinomas as compared with benign ovarian tumours and normal ovaries. Clin Sci (Lond). 78:155–158. 1990.
11	Batra S and Iosif CS: Elevated concentrations of mitochondrial peripheral benzodiazepine receptors in ovarian tumors. Int J Oncol. 12:1295–1298. 1998.PubMed/NCBI
12	Venturini I, Alho H, Podkletnova I, Corsi L, Rybnikova E, Pellicci R, Baraldi M, Pelto-Huikko M, Helén P and Zeneroli ML: Increased expression of peripheral benzodiazepine receptors and diazepam binding inhibitor in human tumors sited in the liver. Life Sci. 65:2223–2231. 1999. View Article : Google Scholar : PubMed/NCBI
13	Papadopoulos V: Peripheral-type benzodiazepine/diazepam binding inhibitor receptor: biological role in steroidogenic cell function. Endocr Rev. 14:222–240. 1993.PubMed/NCBI
14	Wu X and Gallo KA: The 18-kDa translocator protein (TSPO) disrupts mammary epithelial morphogenesis and promotes breast cancer cell migration. PLoS One. 8:e712582013. View Article : Google Scholar : PubMed/NCBI
15	Beinlich A, Strohmeier R, Kaufmann M and Kuhl H: Relation of cell proliferation to expression of peripheral benzodiazepine receptors in human breast cancer cell lines. Biochem Pharmacol. 60:397–402. 2000. View Article : Google Scholar : PubMed/NCBI
16	Landau M, Weizman A, Zoref-Shani E, Beery E, Wasseman L, Landau O, Gavish M, Brenner S and Nordenberg J: Antiproliferative and differentiating effects of benzodiazepine receptor ligands on B16 melanoma cells. Biochem Pharmacol. 56:1029–1034. 1998. View Article : Google Scholar : PubMed/NCBI
17	Ikezaki K and Black KL: Stimulation of cell growth and DNA synthesis by peripheral benzodiazepine. Cancer Lett. 49:115–120. 1990. View Article : Google Scholar : PubMed/NCBI
18	Maaser K, Höpfner M, Jansen A, et al: Specific ligands of the peripheral benzodiazepine receptor induce apoptosis and cell cycle arrest in human colorectal cancer cells. Br J Cancer. 85:1771–1780. 2001. View Article : Google Scholar : PubMed/NCBI
19	Alexander BE, Roller E and Klotz U: Characterization of peripheral-type benzodiazepine binding sites on human lymphocytes and lymphoma cell lines and their role in cell growth. Biochem Pharmacol. 44:269–274. 1992. View Article : Google Scholar : PubMed/NCBI
20	Canat X, Carayon P, Bouaboula M, Cahard D, Shire D, Roque C, Le Fur G and Casellas P: Distribution profile and properties of peripheral-type benzodiazepine receptors on human hemopoietic cells. Life Sci. 52:107–118. 1993. View Article : Google Scholar : PubMed/NCBI
21	O’Brien ER, Kersemans V, Tredwell M, Checa B, Serres S, Soto MS, Gouverneur V, Leppert D, Anthony DC and Sibson NR: Glial activation in the early stages of brain metastasis: TSPO as a diagnostic biomarker. J Nucl Med. 55:275–280. 2014. View Article : Google Scholar
22	Beinlich A, Strohmeier R, Kaufmann M and Kuhl H: Specific binding of benzodiazepines to human breast cancer cell lines. Life Sci. 65:2099–2108. 1999. View Article : Google Scholar : PubMed/NCBI
23	Hardwick M, Fertikh D, Culty M, Li H, Vidic B and Papadopoulos V: Peripheral-type benzodiazepine receptor (PBR) in human breast cancer: correlation of breast cancer cell aggressive phenotype with PBR expression, nuclear localization, and PBR-mediated cell proliferation and nuclear transport of cholesterol. Cancer Res. 59:831–842. 1999.PubMed/NCBI
24	Chiorazzi N, Rai KR and Ferrarini M: Chronic lymphocytic leukemia. N Engl J Med. 352:804–815. 2005. View Article : Google Scholar : PubMed/NCBI
25	Cheson BD, Bennett JM, Grever M, Kay N, Keating MJ, O’Brien S and Rai KR: National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood. 87:4990–4997. 1996.PubMed/NCBI
26	Correale P, Campoccia G, Tsang KY, et al: Recruitment of dendritic cells and enhanced antigen specific immune-reactivity in cancer patients treated with hr-GM-CSF (Molgramostim) and hr-IL-2: results from a phase Ib clinical trial. Eur J Cancer. 37:892–902. 2001. View Article : Google Scholar : PubMed/NCBI
27	Gomez-Monterrey I, Campiglia P, Scognamiglio I, Vanacore D, Dicitore A, Lombardi A, Caraglia M, Novellino E and Stiuso P: DTNQ-Pro, a mimetic dipeptide, sensitizes human colon cancer cells to 5-fluorouracil treatment. J Amino Acids. 2013:5090562013. View Article : Google Scholar : PubMed/NCBI
28	Tenore GC, Manfra M, Stiuso P, Coppola L, Russo M, Ritieni A and Campiglia P: Polyphenolic pattern and in vitro cardioprotective properties of typical red wines from vineyards cultivated in Scafati (Salerno, Italy). Food Chem. 140:803–809. 2013. View Article : Google Scholar : PubMed/NCBI
29	Veenman L and Gavish M: The role of 18 kDa mitochondrial translocator protein (TSPO) in programmed cell death, and effects of steroids on TSPO expression. Curr Mol Med. 12:398–412. 2012.PubMed/NCBI
30	Veenman L, Papadopoulos V and Gavish M: Channel-like functions of the 18-kDa translocator protein (TSPO): regulation of apoptosis and steroidogenesis as part of the host-defense response. Curr Pharm Des. 13:2385–2405. 2007. View Article : Google Scholar : PubMed/NCBI
31	Parker MA, Bazan HE, Marcheselli V, Rodriguez de Turco EB and Bazan NG: Platelet-activating factor induces permeability transition and cytochrome c release in isolated brain mitochondria. J Neurosci Res. 69:39–50. 2002. View Article : Google Scholar : PubMed/NCBI
32	Papadopoulos V, Baraldi M, Guilarte TR, et al: Translocator protein (18 kDa): new nomenclature for the peripheral-type benzodiazepine receptor based on its structure and molecular function. Trends Pharmacol Sci. 27:402–409. 2006. View Article : Google Scholar : PubMed/NCBI
33	Stoebner P E, Carayon P, Casellas P, Portier M, Lavabre-Bertrand T, Cuq P, Cano JP, Meynadier J and Meunier L: Transient protection by peripheral benzodiazepine receptors during the early events of ultraviolet light-induced apoptosis. Cell Death Differ. 8:747–753. 2001. View Article : Google Scholar : PubMed/NCBI
34	Hardwick M, Rone J, Han Z, Haddad B and Papadopoulos V: Peripheral-type benzodiazepine receptor levels correlate with the ability of human breast cancer MDA-MB-231 cell line to grow in SCID mice. Int J Cancer. 94:322–327. 2001. View Article : Google Scholar : PubMed/NCBI
35	Ridnour LA, Thomas DD, Switzer C, et al: Molecular mechanisms for discrete nitric oxide levels in cancer. Nitric Oxide. 19:73–76. 2008. View Article : Google Scholar : PubMed/NCBI
36	Prueitt RL, Boersma BJ, Howe TM, et al: Inflammation and IGF-I activate the Akt pathway in breast cancer. Int J Cancer. 120:796–805. 2007. View Article : Google Scholar